AbbVie says 96 pct patients in oral hepatitis C study show improvement
Dec 10 (Reuters) - AbbVie Inc said a late-stage trial of its experimental hepatitis C therapy showed 96 percent of the patients who had previously failed to respond to treatment had no detectable levels of the virus in the blood after 12 weeks.
The late-stage trial, named Sapphire-II, tested AbbVie's oral hepatitis C treatment in 394 patients who had failed to respond to an earlier treatment with a combination of standard hepatitis C drugs - pegylated interferon and ribavirin.
Last month, AbbVie released data from another late-stage trial, named Sapphire-I, which tested the same therapy in patients who had received no prior treatment.
AbbVie's treatment, known as 3D regimen, combines three drugs along with ribavirin. Sapphire I and II were the first two of six late-stage trials testing the interferon-free treatment.
- Man called Bitcoin's father denies ties, leads LA car chase
- Ukraine standoff intensifies, Russia says sanctions will 'boomerang' |
- Florida mayor fights backyard gun ranges in 'Gunshine State'
- Malaysia Airlines says lost contact with plane carrying 239 people
- Apple loses bid for U.S. ban on Samsung smartphone sales